Quality of life after balloon angioplasty or stenting for acute myocardial infarction
One-year results from the Stent-PAMI trial
Stéphane Rinfret, MD, MSc, FRCP(C)*
,
Cindy L. Grines, MD, FACC
,
Roberta S. Cosgrove, MSc, MPH*,
Kalon K. L. Ho, MD, MSc, FACC*
,
David A. Cox, MD, FACC||,
Bruce R. Brodie, MD, FACC¶,
Marie-Claude Morice, MD, FACC#,
Gregg W. Stone, MD, FACC**,
David J. Cohen, MD, MSc*,*
the Stent-PAMI Investigators
* Cardiovascular Data Analysis Center, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
Cardiovascular Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts, USA
Division of Cardiology, William Beaumont Hospital, Royal Oak, Michigan, USA
|| Mid Carolina Cardiology, Charlotte, North Carolina, USA
¶ LeBauer Health Care, Greensboro, North Carolina, USA
# Institut Cardiovasculaire Paris Sud, Antony, France
** Lenox Hill Hospital, New York, New York, USA

View larger version (28K):
[in a new window]
|
Figure 1 Health-related quality of life 1, 6 and 12 months after stenting versus percutaneous transluminal coronary angioplasty (PTCA) for treatment of acute myocardial infarction, as assessed by the Seattle Angina Questionnaire.
|
|

View larger version (34K):
[in a new window]
|
Figure 2 Health-related quality of life 1, 6 and 12 months after stenting versus percutaneous transluminal coronary angioplasty (PTCA) for treatment of acute myocardial infarction, as assessed with the MOS SF-36 Questionnaire.
|
|
Copyright © 2001 by the American College of Cardiology Foundation.